A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

被引：22
|
作者：
Watts, Justin M. [1 ]
Bradley, Terrence J. [1 ]
Thomassen, Amber [2 ]
Brunner, Andrew M. [3 ]
Minden, Mark D. [4 ]
Papadantonakis, Nikolaos [5 ]
Abedin, Sameem [6 ]
Baines, Amanda J. [7 ]
Barbash, Olena [8 ]
Gorman, Shelby [8 ]
Kremer, Brandon E. [8 ]
Borthakur, Gautam M. [9 ]
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[2] Univ Miami, Sylvester Canc Ctr, Miami, FL USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Hlth Network, Dept Med Oncol & Hematol, Leukemia Program, Princess Margaret Canc Ctr, Toronto, ON, Canada
[5] Taussig Canc Inst, Birmingham, AL USA
[6] Northwestern Mem Hosp, McGaw Med Ctr, Milwaukee, WI USA
[7] GlaxoSmithKline, Stevenage, Herts, England
[8] GlaxoSmithKline, Collegeville, PA USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-130337
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2656
引用
收藏
页数：4
相关论文
共 50 条
  • [41] A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Mattison, Ryan
    Jumonville, Alcee
    Flynn, Patrick James
    Moreno-Aspitia, Alvaro
    Erlichman, Charles
    LaPlant, Betsy
    Juckett, Mark B.
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2061 - 2066
  • [42] A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
    N Daver
    H Kantarjian
    F Ravandi
    E Estey
    X Wang
    G Garcia-Manero
    E Jabbour
    M Konopleva
    S O'Brien
    S Verstovsek
    T Kadia
    C Dinardo
    S Pierce
    X Huang
    N Pemmaraju
    M Diaz-Pines-Mateo
    J Cortes
    G Borthakur
    Leukemia, 2016, 30 : 268 - 273
  • [43] A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
    Daver, N.
    Kantarjian, H.
    Ravandi, F.
    Estey, E.
    Wang, X.
    Garcia-Manero, G.
    Jabbour, E.
    Konopleva, M.
    O'Brien, S.
    Verstovsek, S.
    Kadia, T.
    Dinardo, C.
    Pierce, S.
    Huang, X.
    Pemmaraju, N.
    Diaz-Pines-Mateo, M.
    Cortes, J.
    Borthakur, G.
    LEUKEMIA, 2016, 30 (02) : 268 - 273
  • [44] A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)
    Dawson, Mark
    Stein, Eytan M.
    Huntly, Brian J. P.
    Karadimitris, Anastasios
    Kamdar, Manali
    de larrea, Carlos Fernandez
    Dickinson, Michael J.
    Yeh, Paul Sung-Hao
    Daver, Naval
    Chaidos, Aristeidis
    Tallman, Martin S.
    Jimenez, Raquel
    Horner, Thierry
    Baron, January
    Brennan, John
    Ferron-Brady, Geraldine
    Wu, Yuehui
    Karpinich, Natalie
    Kremer, Brandon
    Dhar, Arindam
    Borthakur, Gautam
    BLOOD, 2017, 130
  • [45] PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Daver, N.
    Kantarjian, H.
    Garcia-Manero, G.
    Jabbour, E.
    Borthakur, G.
    Pierce, S.
    Vaughan, K.
    Vaughan, K.
    Ning, J.
    Gonzalez, G.
    Pemmarjau, N.
    Kadia, T.
    Konopleva, M.
    Andreeff, M.
    DiNardo, C.
    Cortes, J.
    Ward, R.
    Craig, A.
    Ravandi, F.
    HAEMATOLOGICA, 2016, 101 : 187 - 188
  • [46] Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study
    Ragon, Brittany Knick
    Odenike, Olatoyosi
    Baer, Maria R.
    Stock, Wendy
    Borthakur, Gautam
    Patel, Keyur
    Han, Lina
    Chen, Helen
    Ma, Helen
    Joseph, Loren
    Zhao, Yang
    Baggerly, Keith
    Konopleva, Marina
    Jain, Nitin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (07): : 431 - +
  • [47] A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
    Crump, Michael
    Hedley, David
    Kamel-Reid, Suzanne
    Leber, Brian
    Wells, Richard
    Brandwein, Joseph
    Buckstein, Rena
    Kassis, Janine
    Minden, Mark
    Matthews, John
    Robinson, Sue
    Turner, Robert
    Mcintosh, Lynn
    Eisenhauer, Elizabeth
    Seymour, Lesley
    LEUKEMIA & LYMPHOMA, 2010, 51 (02) : 252 - 260
  • [48] A phase I/II clinical study evaluating the safety and clinical activity of enzyme replacement therapy in Mucopolysaccharidosis II (Hunter syndrome).
    Muenzer, J
    Towle, D
    Calikoglu, M
    McCandlless, S
    AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (04) : 582 - 582
  • [49] MEK Inhibitor Binimetinib (MEK162) in Relapse and Refractory Acute Myeloid Leukemia: Results of a Phase I/II Study
    Maiti, Abhishek
    Naqvi, Kiran
    Kadia, Tapan
    Borthakur, Gautam
    Takahashi, Koichi
    Bose, Prithviraj
    Daver, Naval
    Patel, Ami
    Alvarado, Yesid
    Ohanian, Maro
    DiNardo, Courtney
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Ravandi, Farhad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S199 - S199
  • [50] Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
    O'Connell, Casey L.
    Kropf, Patricia L.
    Punwani, Nathan
    Rogers, Dan
    Sposto, Richard
    Gronbaek, Kirsten
    BLOOD, 2018, 132
12345